Use of Phosphodiesterase Inhibitors in Patients with Penile Artery Occlusion

Article Sidebar

PDF
Published: Oct 11, 2023
DOI: https://doi.org/10.47191/ijmscrs/v3-i10-21
Keywords:
phosphodiesterase inhibitors, penile artery occlusion, erectile dysfunction, management.

Main Article Content

Josselyn Nataly Zapata Farfán
Hospital General Regional No. 6 Ignacio García Téllez, cd Madero, Tamaulipas del IMSS
Ruth Nohemi Zapata Farfán
Universidad autónoma de Tamaulipas. Facultad de medicina e ingeniería en sistemas computacionales de Matamoros.

Abstract

Penile artery occlusion is a vascular condition that can lead to erectile dysfunction, significantly affecting a patient's quality of life and psychological well-being. This comprehensive review explores the epidemiology and clinical significance of penile artery occlusion, emphasizing the substantial impact it has on patients' sexual health. The theoretical framework delves into the definition of penile artery occlusion, identifies risk factors contributing to its development, discusses potential complications, and outlines current management strategies. The discussion section evaluates the use of phosphodiesterase inhibitors as a therapeutic approach in patients with penile artery occlusion, providing insights into their mechanisms of action, efficacy, and safety. The conclusion emphasizes the importance of a personalized approach to managing this condition, with phosphodiesterase inhibitors as a valuable option.

Article Details

How to Cite
Josselyn Nataly Zapata Farfán, & Ruth Nohemi Zapata Farfán. (2023). Use of Phosphodiesterase Inhibitors in Patients with Penile Artery Occlusion. International Journal of Medical Science and Clinical Research Studies, 3(10), 2231–2233. https://doi.org/10.47191/ijmscrs/v3-i10-21
Issue
Vol. 3 No. 10 (2023): Volume 03 Issue 10 October 2023
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Yang, Y., Hu, J. L., Ma, Y., Wang, H. X., Chen, Z., Xia, J. G., ... & Chen, B. (2012). Pharmaco-induced erections for penile color-duplex ultrasound: oral PDE5 inhibitors or intracavernosal injection?. International journal of impotence research, 24(5), 191-195.

II. Ravipati, G., McClung, J. A., Aronow, W. S., Peterson, S. J., & Frishman, W. H. (2007). Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. Cardiology in review, 15(2), 76-86.

III. Schwartz, B. G., Jackson, G., Stecher, V. J., Campoli-Richards, D. M., & Kloner, R. A. (2013). Phosphodiesterase type 5 inhibitors improve endothelial function and may benefit cardiovascular conditions. The American Journal of Medicine, 126(3), 192-199.

IV. Salloum, F. N., Ockaili, R. A., Wittkamp, M., Marwaha, V. R., & Kukreja, R. C. (2006). Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial KATP channels in rabbits. Journal of molecular and cellular cardiology, 40(3), 405-411.

V. Gonzalez-Cadavid, N. F., & Rajfer, J. (2010). Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy. Nature Reviews Urology, 7(4), 215-221.

VI. Carson, C. C., & Lue, T. F. (2005). Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU international, 96(3), 257-280.